Skip to content
DataLookout
Menu

NCT07641088

Zishen Yutai Pill for Patients With Recurrent Implantation Failure

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Start date changed from estimate of Jul 1, 2026 to Nov 4, 2026
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 3 of 13 entries
    • Site details revised at 13 of 13 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Live birth rate
Timeframe: About 40 weeks after embryo transfer, up to a maximum duration of 52 weeks after enrollment.

Secondary (13)

Endometrial thickness (ovulation day/endometrial transformation day)
Endometrial pattern (ovulation day/endometrial transformation day)
Endometrial thickness (embryo transfer day)
Endometrial pattern (embryo transfer day)
β-HCG positive rate
Show 8 moreShow less
Implantation rate
Clinical pregnancy rate
Ongoing pregnancy rate
Biochemical pregnancy loss rate
Clinical pregnancy loss rate
Gestational age at delivery
Birthweight
Rate of adverse events

Arms and interventions

ZYP groupExperimental

Zishen Yutai Pill, 5g per time, three times daily

Placebo groupPlacebo comparator

Placebo, 5g per time, three times daily

Drugs: Zishen Yutai Pill, Placebo

Sites

13 sites in 1 country